Introduction
do not require life-long thyroxine (T4) replacement therapy. The cause of transient hypothyroidism after RAI was Radioactive iodine therapy (RAI) is used as the therapy thought to be caused by a short-lived organification defect of choice for hyperthyroidism due to Graves' disease. (3) . However , it has been suggested by ourselves and others With better understanding of the safety of RAI, it is even pre-that the transient development of hypothyroidism could be scribed more frequently for younger patients as the first-line related to changes in antibody parameters. With the availtreatment of choice. Hypothyroidism commonly develops af-ability of more specific tests for characterization of the anter RAI. The incidence of permanent hypothyroidism after tithyroid antibodies, it was observed that RAI could result RAI increases with time but is largely dependent on the dose in alteration of the antibody profiles and that the resulting of 131I administered (1, 2) . In the majority of cases, hypothy-change in antibody profiles could lead us to a change in the roidism is caused by radiation damage to the thyroid.
clinical status of the patients (4, 5) . A transient surge in thyApproximately 10% to 15% of patients may, however, de-rotropin-binding inhibitory immunoglobulin (TBII) has been velop transient hypothyroidism a few months after RAI, but seen in patients with Graves' disease (6) (7) . Re¬ cently, Michelangeli et al. (8) reported that hypothyroidism after RAI could be associated with the production of thyroidblocking antibodies but did not further characterize these.
In the present study, we (10, 11) .
Patients and Methods

Patients
The subjects were part of a group of 120 patients recruited to study the factors that determine hypothyroidism after RAI (18). The Table 2 .
WT cells (Table 3) cording to the thyroid gland size and activity, the incidence of hypothyroidism in the first year is 10%. Thereafter, a 3% an¬ nual cumulative incidence of hypothyroidism is seen due to chronic gradual thyroid atrophy (21). Among those who de¬ velop early and permanent hypothyroidism, 80%-85% de¬ velop the disease as a function of the dose of 131I, i.e., because of higher or ablative doses resultant from our inability to cal¬ culate the exact response to RAI in different individuals. Onethird of U.S. thyroidologists considered hypothyroidism as the desired end point of RAI therapy because they believe this would avoid the risk of recurrent thyrotoxicosis and is also an easier management problem (22) . This is, however, controver¬ sial because it has the net effect of treating one disease by cre¬ ating a second, with its own attendant complications and risks. This report does not attempt to address this complicated issue, but rather focuses on the 10% to 15% of RAI patients develop transient, rather than permanent hypothyroidism, and do not require life-long T4 replacement therapy. We questioned whether the basis for this might be the development of an un¬ usual subtype of TSHR antibodies. TH1  TH2  TH3  TH4  TH5  TH6  TH7  TH8  TH9  TH10  TH11  Median   (interquartile  range)  Nl IgG   TH1  TH2  TH3  TH4  TH5  TH6  TH7   TH8  TH9  TH10 (12, 14) . In the present case, the blockers are also directed at the C-terminus, based on the loss of ac¬ tivity in Mc4 chimeras, in which region TBIIs with blocking activity against TSAbs have been described (12, 14) . No Mc4 data were presented in the Watanabe et al. (14) report. This kind of antibody might be predicted to exhibit conversion activity, wherein anti-IgG could convert the blocker into a stimulator (12, 14) . Unfortunately due to limited IgG supply in our study, we could not determine the conversion activ¬ ity of these sera.
Two patients had blocking antibodies that were directed against residues 9-89 of the TSHR similar to some Graves' TBII, termed type II and described previously (12) . This kind of Graves' antibody can activate the inositol phosphate sig¬ nal transduction system. Unfortunately due to limited Ig supply in our study, we could not determine the ability of these IgGs to activate the inositol phosphate or arachidonate signal transduction system (12, 16 
